Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964576 | 0.84 | ADORA3 (0.67) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5689838 | 0.84 | ADORA3 (0.67) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL25311691 | 0.82 | ADORA2A (0.68) | ADORA2AADORA3ADORA2BADORA1ALDH1A1 | |
| SCHEMBL258935 | 0.82 | ADORA3 (0.59) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5706773 | 0.82 | ADORA2A (0.75) | ADORA2AADORA3ADORA2BADORA1ALDH1A1 | |
| SCHEMBL8102694 | 0.80 | ADORA2A (0.84) | ADORA2AADORA3ADORA2BADORA1ALDH1A1 | |
| SCHEMBL6939834 | 0.80 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5359028 | 0.80 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5736214 | 0.80 | ADORA2A (0.86) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5736195 | 0.80 | ADORA2A (0.86) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205671-A1 | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | EMORY UNIVERSITY | 2006-09-14 | — | — | US | claimed |
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100047798-A1 | ADENOSINE A1 AND A3 RECEPTOR GENE SEQUENCE VARIATIONS FOR PREDICTING DISEASE OUTCOME AND TREATMENT OUTCOME | THOMAS JEFFERSON UNIVERSITY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20060205671-A1 | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | EMORY UNIVERSITY | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047798-A1 | ADENOSINE A1 AND A3 RECEPTOR GENE SEQUENCE VARIATIONS FOR PREDICTING DISEASE OUTCOME AND TREATMENT OUTCOME | ADORA3, ADORA1, ADORA2A | ADORA2A 3/4885ADORA3 1/4885ADORA2B 4/4885 |
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA3 4/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.